Eli Lilly, Mounjaro and Zepbound
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Eli Lilly’s stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro, Zepbound
Eli Lilly shares popped early Tuesday after the drugmaker reported first-quarter profit that topped estimates amid strong demand for diabetes and weight-loss drugs.
Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Eli Lilly raises earnings guidance as it ramps up Mounjaro, Zepbound manufacturing
Eli Lilly raised its full-year guidance while it reported strong first-quarter sales of Zepbound, its obesity drug.
Zepbound and Mounjaro improve sleep apnea symptoms, Eli Lilly trial shows
A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms. Tirzepatide, the main ingredient in these medications, reduced symptom severity by nearly two-thirds.
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs soar
Then $75 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.
Eli Lilly hikes sales guidance by $2bn, shares jump
Shares in Eli Lilly jumped on Wall Street on Tuesday after the American pharma giant beat quarterly profit forecasts and hiked its full-year sales guidance by $2bn, helped by surging demand for its weight-loss drug Zepbound.
Benefits Pro3d
Weight loss drug shortage: Zepbound and Wegovy in short supply, says FDA
Most doses of Zepbound have limited availability because of "demand increase for the drug," while only the highest dose of ...
Everyday Health on MSN4d
Wegovy and Zepbound Shortages Will Last Until Summer
The FDA anticipates limited availability of most doses of the GLP-1 weight loss drugs Wegovy and Zepbound at least through ...
Discover Magazine on MSN3d
The Difference Between Zepbound and Ozempic, and How They Work
The active ingredients in these popular type 2 diabetes treatments are being used to treat a wide range of health conditions.
Weight Loss Drug Zepbound May Help Sleep Apnea, Study Finds
The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe ...
FiercePharma3d
Facing pricing pressure from Lilly's Zepbound, Novo Nordisk scales Wegovy supply
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...
Everyday Health on MSN12d
Zepbound and Mounjaro Might Help Reduce Obstructive Sleep Apnea Symptoms
Tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced sleep apnea symptoms in people with obesity, whether or ...
All Eyes Are on Zepbound Sales as Lilly Reports Earnings
Lilly shares are up 82% over the past 12 months and 26% so far this year. Investors, and the general public, have been ...
Inside Edition4d
How Diabetes Patients Are Impacted by Drug Shortage
Some people are having a really tough time finding their weight-loss medication. Kayla Donatucci drove 400 miles roundtrip, ...